Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up?
about
Myeloid malignancies: mutations, models and managementAKT is a therapeutic target in myeloproliferative neoplasmsSurvival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate-pair sequencing.Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemiaJAK2 exon 14 skipping in patients with primary myelofibrosis: a minor splice variant modulated by the JAK2-V617F allele burden.Current and future treatment options for polycythemia vera.TET proteins and 5-methylcytosine oxidation in hematological cancersMolecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2aEpigenetics of hematopoiesis and hematological malignancies.How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.Protein kinase Cɛ inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients.The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark surveyEvaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis.Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly.Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway.
P2860
Q27000577-DFA07819-5826-4600-8B44-47C65D856286Q33623277-C4FD0939-13DB-47DB-B03E-429702153B12Q34037065-8B8E23E0-D161-43AD-9011-FF7A2997D7FAQ34348505-E5D4B20E-9B75-4566-B0B0-50141BA83E63Q35217865-AF76A1C8-B167-4493-8448-22395F999473Q35548472-0638AA5D-EB97-4E32-B45B-66F9AB3ACD8DQ35572748-6B16E50D-4DC9-4A93-8583-1A677CE9BD8EQ36197509-60A04E4F-343F-42CE-8812-897F65A1934FQ37083947-273F010F-81EA-48A2-9D8C-6B685C6225E9Q37343797-FC94CE3F-63F4-4362-9C54-3CD6F17F60B1Q38740700-54073C46-A9A8-43A7-80C8-21D445D92879Q40727272-6CA38F9C-8732-405A-8D3A-A7958266AC1EQ41508203-2B387B80-779C-480A-B619-9AFE7831AFF6Q49545526-1F78EC3C-2DDE-4645-942B-2FE5876A1A3FQ49689930-9481DAE2-00FC-4117-BDB2-BB6B08FA9E66Q55266073-944C9E6D-7AB8-4732-87D5-AEB7C5DEFED6
P2860
Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up?
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Mutations galore in myeloproli ...... eal Spartacus please stand up?
@en
Mutations galore in myeloproli ...... eal Spartacus please stand up?
@nl
type
label
Mutations galore in myeloproli ...... eal Spartacus please stand up?
@en
Mutations galore in myeloproli ...... eal Spartacus please stand up?
@nl
prefLabel
Mutations galore in myeloproli ...... eal Spartacus please stand up?
@en
Mutations galore in myeloproli ...... eal Spartacus please stand up?
@nl
P2860
P356
P1433
P1476
Mutations galore in myeloproli ...... eal Spartacus please stand up?
@en
P2860
P2888
P304
P356
10.1038/LEU.2011.92
P577
2011-07-01T00:00:00Z